TY - JOUR A1 - Radbruch, Moritz A1 - Pischon, Hannah A1 - Ostrowski, Anja A1 - Volz, Pierre A1 - Brodwolf, Robert A1 - Neumann, Falko A1 - Unbehauen, Michael A1 - Kleuser, Burkhard A1 - Haag, Rainer A1 - Ma, Nan A1 - Alexiev, Ulrike A1 - Mundhenk, Lars A1 - Gruber, Achim D. T1 - Dendritic core-multishell nanocarriers in murine models of healthy and atopic skin JF - Nanoscale Research Letters N2 - Dendritic hPG-amid-C18-mPEG core-multishell nanocarriers (CMS) represent a novel class of unimolecular micelles that hold great potential as drug transporters, e. g., to facilitate topical therapy in skin diseases. Atopic dermatitis is among the most common inflammatory skin disorders with complex barrier alterations which may affect the efficacy of topical treatment. Here, we tested the penetration behavior and identified target structures of unloaded CMS after topical administration in healthy mice and in mice with oxazolone-induced atopic dermatitis. We further examined whole body distribution and possible systemic side effects after simulating high dosage dermal penetration by subcutaneous injection. Following topical administration, CMS accumulated in the stratum corneum without penetration into deeper viable epidermal layers. The same was observed in atopic dermatitis mice, indicating that barrier alterations in atopic dermatitis had no influence on the penetration of CMS. Following subcutaneous injection, CMS were deposited in the regional lymph nodes as well as in liver, spleen, lung, and kidney. However, in vitro toxicity tests, clinical data, and morphometry-assisted histopathological analyses yielded no evidence of any toxic or otherwise adverse local or systemic effects of CMS, nor did they affect the severity or course of atopic dermatitis. Taken together, CMS accumulate in the stratum corneum in both healthy and inflammatory skin and appear to be highly biocompatible in the mouse even under conditions of atopic dermatitis and thus could potentially serve to create a depot for anti-inflammatory drugs in the skin. KW - CMS KW - Skin KW - Topical treatment KW - Dermal delivery KW - Atopic dermatitis KW - Oxazolone KW - Fluorescence lifetime imaging microscopy KW - Nanomaterials KW - Multi-domain nanoparticles KW - Penetration enhancement Y1 - 2017 U6 - https://doi.org/10.1186/s11671-017-1835-0 SN - 1556-276X VL - 12 IS - 64 PB - Springer CY - New York ER - TY - GEN A1 - Radbruch, Moritz A1 - Pischon, Hannah A1 - Ostrowski, Anja A1 - Volz, Pierre A1 - Brodwolf, Robert A1 - Neumann, Falko A1 - Unbehauen, Michael A1 - Kleuser, Burkhard A1 - Haag, Rainer A1 - Ma, Nan A1 - Alexiev, Ulrike A1 - Mundhenk, Lars A1 - Gruber, Achim D. T1 - Dendritic core-multishell nanocarriers in murine models of healthy and atopic skin T2 - Postprints der Universität Potsdam Mathematisch-Naturwissenschaftliche Reihe N2 - Dendritic hPG-amid-C18-mPEG core-multishell nanocarriers (CMS) represent a novel class of unimolecular micelles that hold great potential as drug transporters, e. g., to facilitate topical therapy in skin diseases. Atopic dermatitis is among the most common inflammatory skin disorders with complex barrier alterations which may affect the efficacy of topical treatment. Here, we tested the penetration behavior and identified target structures of unloaded CMS after topical administration in healthy mice and in mice with oxazolone-induced atopic dermatitis. We further examined whole body distribution and possible systemic side effects after simulating high dosage dermal penetration by subcutaneous injection. Following topical administration, CMS accumulated in the stratum corneum without penetration into deeper viable epidermal layers. The same was observed in atopic dermatitis mice, indicating that barrier alterations in atopic dermatitis had no influence on the penetration of CMS. Following subcutaneous injection, CMS were deposited in the regional lymph nodes as well as in liver, spleen, lung, and kidney. However, in vitro toxicity tests, clinical data, and morphometry-assisted histopathological analyses yielded no evidence of any toxic or otherwise adverse local or systemic effects of CMS, nor did they affect the severity or course of atopic dermatitis. Taken together, CMS accumulate in the stratum corneum in both healthy and inflammatory skin and appear to be highly biocompatible in the mouse even under conditions of atopic dermatitis and thus could potentially serve to create a depot for anti-inflammatory drugs in the skin. T3 - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 724 KW - CMS KW - skin KW - topical treatment KW - dermal delivery KW - atopic dermatitis KW - oxazolone KW - fluorescence lifetime imaging microscopy KW - nanomaterials KW - multi-domain nanoparticles KW - penetration enhancement Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-430136 SN - 1866-8372 IS - 724 ER - TY - JOUR A1 - Li, Mingjun A1 - Gao, Lingyan A1 - Schlaich, Christoph A1 - Zhang, Jianguang A1 - Donskyi, Ievgen S. A1 - Yu, Guozhi A1 - Li, Wenzhong A1 - Tu, Zhaoxu A1 - Rolff, Jens A1 - Schwerdtle, Tanja A1 - Haag, Rainer A1 - Ma, Nan T1 - Construction of Functional Coatings with Durable and Broad-Spectrum Antibacterial Potential Based on Mussel-Inspired Dendritic Polyglycerol and in Situ-Formed Copper Nanoparticles JF - ACS applied materials & interfaces N2 - A novel surface coating with durable broad-spectrum antibacterial ability was prepared based on mussel inspired dendritic polyglycerol (MI-dPG) embedded with copper nanoparticles (Cu NPs). The functional surface coating is fabricated via a facile dip-coating process followed by in situ reduction of copper ions with a MI-dPG coating to introduce Cu NPs into the coating matrix. This coating has been demonstrated to possess efficient long-term antibacterial properties against Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and kanamycin-resistant E. coli through an "attract-kill-release" strategy. The synergistic antibacterial activity of the coating was shown by the combination of two functions of the contact killing, reactive oxygen species production and Cu ions released from the coating. Furthermore, this coating inhibited biofilm formation and showed good compatibility to eukaryotic cells. Thus, this newly developed Cu NP-incorporated MI-dPG surface coating may find potential application in the design of antimicrobial coating, such as implantable devices. KW - Cu NP-incorporated MI-dPG coating KW - universal coating KW - in situ chemical reduction KW - antibacterial effect KW - drug-resistant bacteria Y1 - 2017 U6 - https://doi.org/10.1021/acsami.7b10541 SN - 1944-8244 VL - 9 SP - 35411 EP - 35418 PB - American Chemical Society CY - Washington ER -